相关实验视频

Updated: Jun 13, 2025

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

7,4'-dimethoxy-3-hydroxyflavone是一种具有抗氧化活性的蛋白酶激活受体4 (PAR4) 抑制剂,可以改善糖尿病内皮功能障碍

Ju-Ying Tsai¹, Hui-Ching Hsu¹, Chi-Jung Tai^2,3

¹Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.

British journal of pharmacology

|June 12, 2025

概括

高血糖水平通过增加蛋白酶激活受体4 (PAR4) 来加剧糖尿病血管问题. 一种类黄化合物,7,4'-dimethoxy-3-hydroxyflavone (DMF-OH),通过向PAR4和活性氧物种 (ROS),有效地减少了这些问题.

科学领域:

心血管生物学心血管生物学
内分泌学在内分泌学.
药理学药理学是一个学科.

背景情况:

糖尿病血管并发症与高血糖引起的蛋白酶激活受体4 (PAR4) 有关.
内皮功能障碍是糖尿病血管病变的关键早期事件.

研究的目的:

为了调查7,4′-二甲基-3-基黄 (DMF-OH),一个PAR4抗剂,是否可以改善高糖血症相关的内皮功能障碍.
探索PAR4在糖尿病内皮功能障碍中的作用.

主要方法:

采用了一种因斯特佐托辛诱导的糖尿病小鼠模型和高葡萄糖治疗的人体内皮细胞.
检查了PAR4表达和内皮功能障碍标志物.
使用了选择性PAR4抗剂和shRNA介导的淘汰作用.

主要成果:

糖尿病小鼠显示血管PAR4增加,与内皮功能障碍有关 (促炎性细胞因子,氧化应激,组织因子).
在糖尿病小鼠中,DMF-OH的使用改善了这些异常.
高葡萄糖诱导了PAR4表达,并加剧了内皮细胞中的炎症前/血凝前状态,这些状态被DMF-OH降低.
此外,DMF-OH还抑制了依赖ROS的NF-κB激活.

结论:

高血糖引起的PAR4在加重糖尿病内皮功能障碍方面发挥着重要作用.
准PAR4和活性氧物种 (ROS) 是糖尿病血管并发症的新治疗策略.

关键词:

在 PAR4 中,这就是ROSOS ROS.内皮质功能障碍在内皮质功能障碍血糖过高的高血糖症是什么

更多相关视频

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...